Premium
P3‐244: Toward the novel method of treatment for Alzheimer's disease: Extra‐corporeal Aβ removal system (EARS)
Author(s) -
Kawaguchi Kazunori,
Kitaguchi Nobuya,
Nakai Shigeru,
Murakami Kazutaka,
Hara Hideo,
Mutoh Tatsuro,
Sugiyama Satoshi
Publication year - 2009
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2009.04.1017
Subject(s) - chromatography , adsorption , medicine , chemistry , cellulose , surgery , biochemistry , organic chemistry
butylcholinesterase with cognition (CNTB) were correlated; r1⁄40.56 and r1⁄40.65, respectively. 2. Three gamma secretases data include: a. 27 subjects were administered single doses of MK-0752. CSF Abeta declined over a 4-12 hour period in 18 of 19 subjects receiving >300 mg. Mean CSF Abeta40 was substantially reduced (>40%) at 12 hours after MK0752 > 500 mg. This effect was sustained over 24 hr at the highest dose of 1000 mg. b. BMS-708163 demonstrated a more than 25% reduction in CSF Abeta40 with single doses that approximate the concentration range for safe and tolerable multiple dosing regimens. c. In AD subjects, mean percent increases from baseline in CSF Abeta40 concentrations appeared to be less in elderly subjects receiving GSI-953 than in those receiving placebo at most time points. 4. An algorithm for power calculations to assess a proteomic change in with treatment will be provided. 5. These data demonstrate the improved reliability to detect a change in Abeta using an ’AUC’ vs. a single time point approach. Conclusions: Timed interval CSF sampling by indwelling catheterization can is a valuable corroborative biomarker for drug effect. CSF studies with drugs, which modify amyloid protein production or clearance, or inhibit acetylcholine esterase, can be instructive in selecting dosage for development. CSF also is useful in conducting pilot studies to investigate proteomic changes.